1601 - 1610 of 6230 Results
Title
Year
-
OPENTitle: The Regulation of ImmunityJournal Name: The Journal of ImmunologyPublisher: Oxford University Press (OUP)Vol: 208Issue #: 11Start Page: 2450End Page: 2455Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.4049/jimmunol.2290007Best OA location URL: https://journals.aai.org/jimmunol/article-pdf/208/11/2450/1501657/ji2290007.pdfCitation Count: 0
- Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel2022OPENTitle: Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert PanelJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 11Issue #: 4Start Page: 1571End Page: 1582Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-022-00388-yBest OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-022-00388-y.pdfCitation Count: 7
-
OPENTitle: Resilience and Trauma among Patients with Parkinson’s Disease during the COVID-19 PandemicJournal Name: Journal of Movement DisordersPublisher: The Korean Movement Disorder SocietyVol: 15Issue #: 1Start Page: 77End Page: 79Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.14802/jmd.20126Best OA location URL: http://e-jmd.org/upload/jmd-20126.pdfCitation Count: 3
- Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses2022OPENTitle: Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc AnalysesJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 11Issue #: 2Start Page: 711End Page: 723Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-022-00332-0Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-022-00332-0.pdfCitation Count: 1
- Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment2022OPENTitle: Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label TreatmentJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 11Issue #: 1Start Page: 459End Page: 469Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-021-00317-5Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-021-00317-5.pdfCitation Count: 5
- Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries2022OPENTitle: Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 CountriesJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 11Issue #: 1Start Page: 303End Page: 318Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-021-00313-9Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-021-00313-9.pdfCitation Count: 11
- Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial2022OPENTitle: Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON TrialJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 11Issue #: 3Start Page: 1409End Page: 1425Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-022-00371-7Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-022-00371-7.pdfCitation Count: 7
-
OPENTitle: A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein ToxicityJournal Name: NeurotherapeuticsPublisher: Elsevier BVVol: 19Issue #: 3Start Page: 1018End Page: 1036Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1007/s13311-022-01199-7Best OA location URL: https://link.springer.com/content/pdf/10.1007/s13311-022-01199-7.pdfCitation Count: 14
- The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England2022OPENTitle: The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in EnglandJournal Name: PharmacoEconomicsPublisher: Springer Science and Business Media LLCVol: 40Issue #: 5Start Page: 559End Page: 574Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40273-022-01132-yBest OA location URL: https://link.springer.com/content/pdf/10.1007/s40273-022-01132-y.pdfCitation Count: 10
- An open-label prospective pilot trial of nucleus accumbens deep brain stimulation for children with autism spectrum disorder and severe, refractory self-injurious behavior: study protocol2022OPENTitle: An open-label prospective pilot trial of nucleus accumbens deep brain stimulation for children with autism spectrum disorder and severe, refractory self-injurious behavior: study protocolJournal Name: Pilot and Feasibility StudiesPublisher: Springer Science and Business Media LLCVol: 8Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s40814-022-00988-3Best OA location URL: https://pilotfeasibilitystudies.biomedcentral.com/track/pdf/10.1186/s40814-022-00988-3Citation Count: 11